fda warning letters compounded semaglutide telehealth 2024 2025 September 15, 2025: company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA issued 30 warning letters

Medical Review: A US-licensed physician reviews your profile and prescribes your starting dose

The phase 3 weight loss study for Retatrutide is expected to finish in early 2026, paving the way for its potential approval and widespread use

For people with diabetes, the American Diabetes Association recommends checking both eGFR and urine albumin-to-creatinine ratio at least annually, or more frequently with existing kidney disease

Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners

It also promotes healthy systemic metabolic outcomes within the gut lining